HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

q-griffithsin

a recombinant oxidation-resistant variant of griffithsin; an anti-HIV lectin-based microbicide

Also Known As:

Q-GRFT

Networked: 6 relevant articles (3 outcomes, 5 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins: 1
- Proteins: 484843

Experts

1.	Decker, John S: 2 articles (04/2022 - 01/2022)
2.	Lynch, Michael D: 2 articles (04/2022 - 01/2022)
3.	Menacho-Melgar, Romel: 2 articles (04/2022 - 01/2022)
4.	Fuqua, Joshua L: 2 articles (10/2021 - 01/2021)
5.	Palmer, Kenneth E: 2 articles (10/2021 - 01/2021)
6.	Kouokam, Joseph C: 1 article (10/2021)
7.	Lasnik, Amanda B: 1 article (10/2021)
8.	Nabeta, Henry W: 1 article (10/2021)
9.	Fried, Joel R: 1 article (01/2021)
10.	Minooei, Farnaz: 1 article (01/2021)

Related Diseases

1.	COVID-19 12/01/2023 - "SPRAY PAL validation was undertaken as part of an ongoing phase 1 clinical trial designed to test the safety, pharmacokinetics and tolerability of intranasally administered Q-GRFT for the prevention of SARS-CoV-2 infection. " 12/01/2023 - "Development and validation of a product acceptability questionnaire for intranasal Q-Griffithsin COVID-19 prophylaxis (SPRAY PAL)." 04/01/2022 - "Here we report an improved bioprocess for Q-Griffithsin, a broad-spectrum antiviral currently in clinical trials for COVID-19. " 01/03/2022 - "Here we report an improved bioprocess for Q-Griffithsin, a broad-spectrum antiviral currently in clinical trials for COVID-19. " 12/01/2023 - "Here, we report the development and validation of a product acceptability questionnaire (SPRAY PAL) assessing feasibility, acceptability and tolerability of an intranasal Q-Griffithsin (Q-GRFT) drug product designed for COVID-19 prophylaxis. "
2.	Autolysis 04/01/2022 - "Integrated autolysis, DNA hydrolysis and precipitation enables an improved bioprocess for Q-Griffithsin, a broad-spectrum antiviral and clinical-stage anti-COVID-19 candidate." 01/03/2022 - "Integrated Autolysis, DNA Hydrolysis and Precipitation Enables an Improved Bioprocess for Q-Griffithsin, a Broad-Spectrum Antiviral and Clinical-Stage anti-COVID-19 Candidate."
3.	Candidiasis (Moniliasis) 10/31/2021 - "In conclusion, this novel antifungal activity suggests that Q-GRFT is potentially an ideal drug candidate and represents an alternative strategy for the prevention and treatment of candidiasis. " 01/01/2022 - "The goal of this study was to evaluate the efficacy of a prototype Q-GRFT dosage form in prophylactic and therapeutic murine models of vaginal candidiasis, through microbiologic, histopathologic, and immune studies. " 01/01/2022 - "Our results demonstrate that Q-GRFT has significant preventive and therapeutic activity in vaginal candidiasis offering additional benefit as a topical microbicide for prevention of HIV-1 and HSV-2 transmission." 01/01/2022 - "Antiviral lectin Q-Griffithsin suppresses fungal infection in murine models of vaginal candidiasis."
4.	Mycoses (Diseases, Fungus) 10/31/2021 - "Our study has identified Q-GRFT, a broad-spectrum antiviral protein that harbors growth-inhibitory activity against several Candida strains, as a potential candidate for the prevention and treatment of fungal infections." 01/01/2022 - "Antiviral lectin Q-Griffithsin suppresses fungal infection in murine models of vaginal candidiasis."
5.	Infections 01/01/2021 - "In vitro Study on Synergistic Interactions Between Free and Encapsulated Q-Griffithsin and Antiretrovirals Against HIV-1 Infection."

Related Drugs and Biologics

1.	Antiviral Agents (Antivirals)
2.	DNA (Deoxyribonucleic Acid)
3.	Dosage Forms (Dosage Form)
4.	Proteins (Proteins, Gene)
5.	q-griffithsin
6.	Lectins
7.	Anti-Infective Agents (Microbicides)